Michael Sherman, MD, chief medical officer at Harvard Pilgrim Health Care, discusses the challenges of moving towards performance-based risk-sharing agreements and where they would work best for certain treatments.
Michael Sherman, MD, chief medical officer at Harvard Pilgrim Health Care, discusses the challenges of moving towards performance-based risk-sharing agreements and where they would work best for certain treatments.
Transcript (slightly modified)
What are the challenges of negotiating performance-based risk-sharing agreements?
We’ve been doing risk-sharing agreements with providers for many years. Pharmaceuticals stand out as being a bit different than all other parts of the care delivery continuum. The fact is there is an existing status quo and just as it’s hard to move away from fee-for-service with providers, moving from pay-for-pills to paying for outcomes feels a bit hard. Part of the reason is that pharmaceutical companies haven’t felt the need or the urgency to move in this direction. Now that we have some successes, I think many of them are seeing them as an opportunity, not just as a threat.
Are there certain treatments or disease states where performance-based, risk-sharing agreements work best?
Absolutely, one of the constraints is the disease state. First, there have to be diseases where there is an outcome measure, like reduced cholesterol, like improved hemoglobin A1C for diabetes, like reduced hospitalization. They need to be things where there are objective measures and where they are not impossible or hard to collect. Also, where there is a clear relationship between the treatment and that measure. For cases where there are multiple drug regimens it may be complicated, in cases where the natural course of the disease may be variable it may be hard to do this, and where the impact is many years outed, it’s very hard to do. I estimate there is probably 20% to 25% of drugs where this is a good approach.
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
SDOH in Cancer Care Highlight Multifactorial Equity Issues
December 6th 2023A trio of speakers addressed the importance of social determinants of health (SDOH) in cancer care on day 1 of the 46th annual San Antonio Breast Cancer Symposium in the session, “Social Determinants of Health: Impact on Cancer Care.”
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More